Terminated PHASE3 NCT00389519

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study Assessing the Efficacy, Safety, and Dose-Response of Ramipril for the Treatment of Hypertension in Children and Adolescents

Sponsor: Pfizer

Conditions Hypertension

Interventions placebo ramipril

Updated 10 times since 2017 Last updated: Jun 6, 2012 Started: Oct 31, 2006 Primary completion: Nov 30, 2007 Completion: Nov 30, 2007

Listed as NCT00389519, this PHASE3 trial focuses on Hypertension and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 10 times since 2006, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Jan 2017 — Aug 2017 [monthly]

Terminated PHASE3

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Atlanta, United States , Augusta, United States , Bangalore, India , Barranquilla, Colombia , Beaumont, United States , Benoni, South Africa , Beverly Hills, United States , Bogotá, Colombia , Bridgeton, United States and 69 more locations